MedTrace Logo

Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies

NCT07196280 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2025-09-29

No results posted yet for this study

Summary

To assess the impact of 5-alpha reductase inhibitors (5-ARIs) on the incidence of atherosclerotic cardiovascular disease (ASCVD) in patients with benign prostatic hyperplasia (BPH).

Conditions

  • Atherosclerotic Cardiovascular Disease (ASCVD)
  • Benign Prostatic Hypertrophy (BPH)

Interventions

DRUG

5-Alpha Reductase Inhibitors

Building on prior studies, drug exposure was defined as receiving 5-ARIs on at least two separate occasions, with an interval of no more than 180 days between prescriptions. Based on exposure status, the cohort was stratified into two groups.

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Eligibility

Min Age
45 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-01
Primary Completion
2022-12-31
Completion
2022-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07196280 on ClinicalTrials.gov